Survival analysis revealed that when FGL1, LAG3, TNFRSF18, and IL-23A were highly expressed, the prognosis of patients was worse, while JAK1, JAK2, and LDHA were on the contrary (Supplementary Figure S3), which may provide a new target for immunotherapy of ccRCC. The gene discussed is JAK1; the disease is nonpapillary renal cell carcinoma.